Back

Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration Adverse Event Reporting System

European Heart Journal - Cardiovascular Pharmacotherapy

20 December 2017
Organised by: Logo
Read full article
ESC Journals
You may be interested in
thumbnail
Congress Presentation
Comparative safety and effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndrome. An on treatment analysis from the multicenter CREA ARIAM Andalucia registry
19 March 2022
thumbnail
Congress Presentation
Platelet inhibitory profiles of prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes undergoing percutaneous coronary intervention: results of a randomized feasibility study
1 September 2019
thumbnail
Congress Presentation
Impact of potent P2Y12 inhibitors in adverse events reduction in diabetic patients with Acute Coronary Syndromes. An analysis from ACHILLES Registry.
2 September 2019
thumbnail
Congress Session
Dual antiplatelet therapy titration after percutaneous coronary intervention: when to escalate, de-escalate, withdraw, and more
28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources